Nima Nabavizadeh, M.D., a physician-scientist at OHSU Knight Cancer Institute, is principal investigator for the PATHFINDER 2 study. Results published in Nature Medicine show the GRAIL Galleri test the study is assessing dramatically improves multi-cancer early detection when used with routine screening. (OHSU/Christine Torres Hicks)

Nima Nabavizadeh, M.D., of the OHSU Knight Cancer Institute, with his patient, Franklin Weingarten, at OHSU. The Galleri test caught a rare bile duct cancer in Weingarten, and now he remains cancer-free. (OHSU/Christine Torres Hicks)

Nima Nabavizadeh, M.D., of the OHSU Knight Cancer Institute, with his patient, Bart Dawkins, by the aerial tram. The Galleri test caught Dawkins’ liver cancer early. “I think everybody needs to do this bloodwork. It will potentially save their life,” Dawkins says. (OHSU/Christine Torres Hicks)

El Dr. Nima Nabavizadeh, médico investigador del Knight Cancer Institute de OHSU, es el investigador principal del estudio PATHFINDER 2. Los resultados publicados en Nature Medicine muestran que la prueba Galleri de GRAIL, que se está evaluando en el estudio, mejora drásticamente la detección temprana de múltiples cánceres cuando se usa junto con pruebas de detección de rutina. (OHSU/Christine Torres Hicks)

Nima Nabavizadeh, M.D., of the OHSU Knight Cancer Institute, with his patient, Bart Dawkins, by the aerial tram. The Galleri test caught Dawkins’ liver cancer early. “I think everybody needs to do this bloodwork. It will potentially save their life,” he says. (OHSU/Christine Torres Hicks)

Nima Nabavizadeh, M.D., of the OHSU Knight Cancer Institute, with his patient, Franklin Weingarten, at OHSU. The Galleri test caught a rare bile duct cancer in Weingarten, and now he remains cancer-free. (OHSU/Christine Torres Hicks)